Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2024-03-07 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2023, including total assets, liabilities, equity, revenue, profit, cash flow statements, and comparative figures from 2022. The report is audited by an accounting firm, indicating it is a formal financial report. The content covers comprehensive financial performance and business results for the entire fiscal year, consistent with an Annual Report. The document length is 2292 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it is classified as an Annual Report (10-K). FY 2023
2024-03-07 Chinese
董事会战略委员会议事规则（2024年修订）
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Strategic Committee Work Rules' of a company, detailing the structure, responsibilities, meeting procedures, and governance of the board's strategic committee. It references company law, stock exchange rules, and regulatory requirements but does not contain financial data, earnings, audit results, or shareholder voting outcomes. It is a governance-related document outlining internal rules and committee operations rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length is 2490 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2024-03-07 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the company's internal control evaluation for the year ending December 31, 2023, including detailed descriptions of internal control systems, evaluation scope, standards for identifying control deficiencies, and conclusions on the effectiveness of internal controls. It includes references to financial and non-financial internal control assessments, audit opinions, and compliance with regulatory standards. The document is comprehensive, over 11,000 characters, and contains substantive content on internal control evaluation rather than just an announcement or summary. This type of report is a standalone audit-related report focusing on internal control evaluation and audit results, which fits the category of Audit Report / Information (AR). It is not an Annual Report (10-K) as it does not cover full financial performance or company activity broadly, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains the full report content. Therefore, the correct classification is AR with high confidence. FY 2023
2024-03-07 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告全文" (2023 Annual Report Full Text) of 普洛药业股份有限公司, indicating it is a full annual report. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-07 Chinese
公司章程修订案
Governance Information Classification · 95% confidence The document is titled "公司章程修订案" which translates to "Amendment to the Articles of Association" of 普洛药业股份有限公司. It details proposed revisions to the company's articles of association, including changes to board structure, capital, shareholder meeting procedures, and profit distribution policies. The content is focused on governance rules and internal company regulations rather than financial results or audit opinions. There is no indication of financial statements, audit reports, earnings data, or shareholder voting results. The document is a formal governance-related filing about company bylaws and board/management structure. Therefore, the most appropriate classification is Governance Information (CGR). The document length (over 10,000 characters) and detailed content confirm it is the actual governance document, not just an announcement or summary.
2024-03-07 Chinese
募集资金管理制度（2024年修订）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management and use of funds raised by the company through stock issuance. It includes regulatory references to Chinese securities laws and Shenzhen Stock Exchange rules, and outlines procedures for managing, storing, using, and supervising raised funds. The content is a detailed internal policy or system document related to capital raising and fund management, not a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a brief announcement or presentation. It is a regulatory compliance and internal control document related to capital/financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-03-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.